Germline polymorphisms in MGMT associated with temozolomide-related myelotoxicity risk in patients with glioblastoma treated on NRG Oncology/RTOG 0825 is a research paper published in Neuro-Oncology Advances (2022). On theSindex it has a DataRank of 0. It has been cited 2 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Cancer Institute
Grant: U10CA180868
National Cancer Institute
Grant: U10CA180822
National Cancer Institute
Grant: UG1CA189867
National Cancer Institute
Grant: U24CA196067
National Institutes of Health
Grant: 1R01NR013707
National Institutes of Health
Grant: K07CA181480
NCI NIH HHS
Grant: UG1 CA233277
National Institutes of Health
Grant: 3UG1CA189867-03S1
NRG Oncology NCORP Research Base
National Institutes of Health
Grant: 2U10CA180822-06
NRG Oncology - Statistical and Data Management Center
National Institutes of Health
Grant: 4R01NR013707-04
Toxicity profiling: creating novel paradigms to personalize cancer treatment
National Institutes of Health
Grant: 5U10CA180868-09
NRG Oncology Network Group Operations Center
Wellcome Trust
Grant: unidentified
unidentified
National Institutes of Health
Grant: 5U24CA196067-04
NRG Oncology Biospecimen Bank
National Institutes of Health
Grant: 1K07CA181480-01A1
Lung Cancer Prediction Models Incorporating Exome Data from Extreme Phenotypes
Voices Against Brain Cancer Foundation and Genentech
Fields of Study
Keywords
Sustainable Development Goals